Many startups make the mistake of viewing regulatory affairs – and regulators – as a necessary evil, or barrier to market entry. That can be a huge red flag to investors who know the value of using regulatory as a business and competitive strategy.

October 7, 2019
By Michelle Lott
Many startups make the mistake of viewing regulatory affairs – and regulators – as a necessary evil, or barrier to market entry. That can be a huge red flag to investors who know the value of using regulatory as a business and competitive strategy.
What Investors Need to Know About Start-Ups
Startups have different challenges along the road to market release than do the larger, established medical device organizations. As an
Learn MoreRegulatory Strategy DOES Make a Difference
I have seen some VERY dysfunctional organizations in my day. No matter the size or how long the company has
Learn MoreLooking Beyond the Investor Pitch
As an investor looking into the biotech and medtech industries, you need to know what questions to ask the company
Learn More